Ignite Creation Date:
2025-12-24 @ 4:52 PM
Ignite Modification Date:
2026-03-05 @ 5:41 AM
Study NCT ID:
NCT04551950
Status:
COMPLETED
Last Update Posted:
2024-03-08
First Post:
2020-09-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
Sponsor:
EMD Serono Research & Development Institute, Inc.
Organization:
Study Overview
Official Title:
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2020-001561-36 | EUDRACT_NUMBER | None | View |